Shares of Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report) were down 32.7% during trading on Friday . The stock traded as low as $1.01 and last traded at $1.01. Approximately 2,700 shares traded hands during mid-day trading, an increase of 50% from the average daily volume of 1,800 shares. The stock had previously closed at $1.50.
Silence Therapeutics Price Performance
The company has a 50 day moving average of $2.54 and a 200 day moving average of $5.09.
Silence Therapeutics Company Profile
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
Recommended Stories
- Five stocks we like better than Silence Therapeutics
- Quiet Period Expirations Explained
- MP Materials: Rare Earth Elements Powering the EV Boom
- What is the S&P/TSX Index?
- Verizon’s Turnaround Gains Traction: New Highs Are Likely in 2025
- Expert Stock Trading Psychology Tips
- Bloom Energy: Powering the Future With Decentralized Energy
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
